UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017727
Receipt number R000020520
Scientific Title Corrected VA with Long Term Follow up after AcrySof IOL Implantation
Date of disclosure of the study information 2015/06/01
Last modified on 2016/11/24 13:52:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Corrected VA with Long Term Follow up
after AcrySof IOL Implantation

Acronym

Corrected VA with Long Term Follow up
after AcrySof IOL Implantation

Scientific Title

Corrected VA with Long Term Follow up
after AcrySof IOL Implantation

Scientific Title:Acronym

Corrected VA with Long Term Follow up
after AcrySof IOL Implantation

Region

Japan


Condition

Condition

Cataract

Classification by specialty

Ophthalmology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To demonstrate non-inferiority of AcrySof (acrylic) to control IOLs (silicone and PMMA) in BCVA change at the long-term post-implantation (implantation period is 1994 to 2000) visit.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

BCVA change at the long term post implantation visit from within 3 months after IOL implantation

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

AcrySof group

Interventions/Control_2

PMMA group

Interventions/Control_3

Slicone group

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Willing to provide voluntary consent and able to comprehend and sign the informed consent form
2)Pseudophakic patients who were implanted with an Acrylic (AcrySof), PMMA or silicone IOL from 1994 to 2000.
3)Clear intraocular media in study eyes
4)Best corrected visual acuity (decimal) within 3 months post implantation is 0.8 (decimal VA chart) or more in study eye.
5)Patient who does not have an ocular or systemic condition which may affect visual acuity in study eye.

Key exclusion criteria

1)Patient who has the following complications that may have an impact on visual acuity at the time of the prospective visit in study eye.
-Glaucoma
-Diabetic retinitis
-Ocular inflammatory disease; scleritis, uveitis, herpes corneae, etc.
-Retinal detachment
-Abnormal retina and fovea; Macular degeneration, retinal disease
-Corneal disease, corneal endothelial cell loss, etc.
-History of keratoplasty
-Ocular trauma
-Intraocular surgery post IOL implantation Occur with post capsular Opacification. Eyes that had YAG laser performed or with peripheral opacification (outside the photopic pupil size) will be allowed in the study
2)Previous refractive surgery in study eye
3)Previous IOL exchange in study eye
4)Disqualified by the investigator or the sub investigator because of systemic or ophthalmic diseases

Target sample size

90


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazunori Miyata

Organization

Miyata Eye Hospital

Division name

Miyata Eye Hospital

Zip code


Address

6-3 Kurahara Miyakonojo Miyazaki

TEL

0986-22-1441

Email

miyata@miyata-med.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Koji Hasegawa

Organization

Alcon Japan Ltd.

Division name

Clinical Development, Clinical & Regulatory Affairs

Zip code


Address

1-23-1 Toranomon, Minato-ku, Tokyo

TEL

03-6899-5061

Homepage URL


Email

koji.hasegawa@alcon.com


Sponsor or person

Institute

Alcon Japan Ltd.

Institute

Department

Personal name



Funding Source

Organization

Alcon Japan Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

The mean change in logMAR best-corrected visual acuity from baseline at the long-term post-implantation follow-up visit was 0.01, 0.04, and -0.01 in the AcrySof, silicone, and PMMA groups, respectively. The upper limit of 97.5% one-sided confidence interval of the difference in the change in best-corrected visual acuity between the AcrySof group and each control group was +0.01 logMAR for the silicone group and +0.07 logMAR for the PMMA group, both of which were lower than the non-inferiority margin of +0.1 logMAR.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 03 Month 30 Day

Date of IRB


Anticipated trial start date

2015 Year 06 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective adverse events were observed in the target eye for efficacy analysis of 1 subject (3.2%) in the AcrySof group and in the contralateral eye of 1 subject (3.3%) in the PMMA group. None of these events were considered to be related to the IOL.
Retrospective adverse events were observed in 1 subject (3.2%) in the AcrySof group, 3 subjects (8.1%) in the silicone group, and 4 subjects (13.3%) in the PMMA group. None of these events were considered to be related to the IOL.
A retrospective adverse reaction was observed in 1 subject (2.7%) in the silicone group. The causal relationship between this event and the IOL was considered unknown by the investigator, and the event was therefore classified as an adverse reaction.
No device failures were observed.


Management information

Registered date

2015 Year 05 Month 28 Day

Last modified on

2016 Year 11 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020520


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name